EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting

Wang Chun Kwok iD, Man Fung Tsoi, Sze Him Isaac Leung, Chung Ki Tsui, Terence Chi Chun Tam iD, James Chung Man Ho iD, David Chi Leung Lam iD, Mary Sau Man Ip, Pak Leung Ho iD

Viruses · 2023

DOI: 10.3390/v15030610 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Wang Chun Kwok und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China. Hauptthemen laut MEDLINE: COVID-19, Respiratory Insufficiency. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Microbiology, University of Hong Kong.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While molnupiravir (MOV) and nirmatrelvir–ritonavir (NMV-r) were developed for treatment of mild to moderate COVID-19 infection, there has been a lack of data on the efficacy among unvaccinated adult patients with chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis. A territory-wide retrospective cohort study was conducted in Hong Kong to investigate the efficacy of MOV and NMV-r against severe outcomes of COVID-19 in unvaccinated adult patients with chronic respiratory diseases. A total of 3267 patients were included. NMV-r was effective in preventing respiratory failure (66.6%; 95% CI, 25.6–85.0%, p = 0.007), severe respiratory failure (77.0%; 95% CI, 6.9–94.3%, p = 0.039) with statistical significance, and COVID-19 related hospitalization (43.9%; 95% CI, −1.7–69.0%, p = 0.057) and in-hospital mortality (62.7%; 95% CI, −0.6–86.2, p = 0.051) with borderline statistical significance. MOV was effective in preventing COVID-19 related severe respiratory failure (48.2%; 95% CI 0.5–73.0, p = 0.048) and in-hospital mortality (58.3%; 95% CI 22.9–77.4, p = 0.005) but not hospitalization (p = 0.16) and respiratory failure (p = 0.10). In summary, both NMV-r and MOV are effective for reducing severe outcomes in unvaccinated COVID-19 patients with chronic respiratory diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Respiratory InsufficiencyAdultHumansOutpatientsRitonavirRetrospective StudiesCOVID-19 Drug TreatmentSARS-CoV-2Antiviral AgentsLactamsLeucineNitrilesProlineCytidineHydroxylamines

Stichwörter der Autor:innen

COPDCOVID-19asthmabronchiectasismolnupiravirnirmatrelvir–ritonavir

Substanzen

RitonavirAntiviral AgentsnirmatrelvirLactamsLeucineNitrilesProlinemolnupiravirCytidineHydroxylamines

Autor:innen und Institutionen

  • Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
  • Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester M139PT, UK.
  • Department of Statistics, The Chinese University of Hong Kong, Hong Kong, China.
  • Department of Medicine, Queen Mary Hospital, Hong Kong, China.
  • Department of Microbiology and Carol Yu Centre for Infection, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.

ORCID-Profile: Wang Chun Kwok, Terence Chi Chun Tam, James Chung Man Ho, David Chi Leung Lam, Pak Leung Ho

Förderung

  • Department of Microbiology, University of Hong Kong

Zitieren

APA

Kwok, W. C., Tsoi, M. F., Leung, S. H. I., Tsui, C. K., Tam, T. C. C., Ho, J. C. M., Lam, D. C. L., Ip, M. S. M., & Ho, P. L. (2023). Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting. Viruses. https://doi.org/10.3390/v15030610

Vancouver

Kwok WC, Tsoi MF, Leung SHI, Tsui CK, Tam TCC, Ho JCM, et al. Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting. Viruses. 2023. doi:10.3390/v15030610

BibTeX
@article{Kwok2023,
  author = {Kwok, Wang Chun and Tsoi, Man Fung and Leung, Sze Him Isaac and Tsui, Chung Ki and Tam, Terence Chi Chun and Ho, James Chung Man and Lam, David Chi Leung and Ip, Mary Sau Man and Ho, Pak Leung},
  title = {Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15030610}
}
Kostenlos starten →